Bulk Pharmaceutical API Sources for CLOBEX

Bulk Pharmaceutical API Sources for CLOBEX

Vendor	Vendor Homepage	Vendor Sku	API Url
Hangzhou APIChem Technology		AC-17990
Amadis Chemical		A817657
BioChemPartner		BCP0726000094
BioChemPartner		BCP9000539
AKos Consulting & Solutions		AKOS015951278
TCI (Tokyo Chemical Industry)		C2612
Finetech Industry Limited		FT-0638495

Clobex Active Pharmaceutical Ingredient (API) Sourcing Landscape

Last updated: February 19, 2026

Clobex (clobetasol propionate) is a high-potency topical corticosteroid. Its active pharmaceutical ingredient (API) is primarily manufactured by specialized chemical synthesis facilities. Sourcing strategies focus on API purity, regulatory compliance, and reliable supply chains.

What are the primary API manufacturing regions for clobetasol propionate?

API manufacturing for clobetasol propionate is concentrated in regions with established pharmaceutical chemical industries and robust regulatory oversight. Key manufacturing hubs include:

• India: A significant global producer of APIs, benefiting from cost-effective manufacturing and a large number of Good Manufacturing Practice (GMP) certified facilities.
• China: Another major API exporter, offering competitive pricing and scaled production capabilities.
• Europe: Several European countries, including Germany and Italy, house specialized fine chemical manufacturers that produce high-quality clobetasol propionate API, often meeting stringent European Pharmacopoeia (EP) standards.
• United States: While domestic API production exists, it is typically for specialized or higher-cost segments of the market.

Which regulatory bodies oversee clobetasol propionate API manufacturing and supply?

Regulatory oversight is critical for ensuring API quality and patient safety. Key bodies include:

• U.S. Food and Drug Administration (FDA): Regulates APIs manufactured for the U.S. market. Facilities are subject to FDA inspections, and API manufacturers must file Drug Master Files (DMFs) or provide Certificates of Suitability (CEPs) where applicable.
• European Medicines Agency (EMA): Oversees APIs used in medicinal products within the European Union. CEPs issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) are a common standard.
• Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: Regulates APIs for the Japanese market.
• National regulatory authorities in other significant markets, such as Health Canada, TGA (Australia), and CDSCO (India).

What are the critical quality attributes and specifications for clobetasol propionate API?

Clobetasol propionate API must meet strict specifications to ensure the safety and efficacy of the final drug product. Key attributes and specifications typically include:

• Assay: The purity of clobetasol propionate, usually specified as a percentage (e.g., not less than 98.0% and not more than 102.0% of clobetasol propionate, on the dried basis).
• Related Substances/Impurities: Limits for known and unknown impurities, including degradation products and process-related impurities. These are often quantified using High-Performance Liquid Chromatography (HPLC) and must be below defined thresholds (e.g., individual unknown impurity < 0.10%).
• Residual Solvents: Limits for solvents used during the synthesis process, as defined by ICH (International Council for Harmonisation) guidelines.
• Water Content: Measured by Karl Fischer titration, with a specified maximum limit (e.g., not more than 1.0%).
• Loss on Drying: A measure of volatile matter, with a specified maximum limit.
• Heavy Metals: Limits for contamination by heavy metals.
• Particle Size Distribution: Important for dissolution and bioavailability in topical formulations. Specifications can vary based on the intended formulation.
• Polymorphism: The API may exist in different crystalline forms, which can affect solubility and stability. Manufacturers control and specify the desired polymorphic form.

These specifications are typically detailed in pharmacopoeial monographs (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (EP)) and in the API manufacturer's DMF.

What are the key considerations for selecting a clobetasol propionate API supplier?

Selecting a reliable API supplier involves evaluating several factors:

• Regulatory Compliance:
  • GMP Certification: The facility must be GMP certified by relevant authorities (e.g., FDA, EMA).
  • DMF/CEP Availability: A comprehensive and up-to-date DMF or CEP is essential for regulatory submissions.
  • Inspection History: A review of past regulatory inspection findings is crucial.
• Quality Management System: Robust quality control and quality assurance processes, including change control, deviation management, and batch traceability.
• Supply Chain Reliability:
  • Production Capacity: Ability to meet projected demand volumes.
  • Lead Times: Predictable and consistent lead times for API delivery.
  • Supply Chain Security: Measures to prevent counterfeit or substandard APIs from entering the supply chain.
  • Business Continuity Planning: Robust plans for managing disruptions (e.g., natural disasters, geopolitical events).
• Technical Capabilities:
  • Analytical Capabilities: Sophisticated in-house testing and method validation.
  • Process Understanding: Deep knowledge of the synthesis process and impurity profiling.
  • Technical Support: Responsiveness and expertise in addressing technical inquiries.
• Cost and Commercial Terms: Competitive pricing, payment terms, and contract stability.
• Auditing: The ability for prospective customers to conduct thorough on-site audits of the manufacturing facility.

How does patent protection impact the sourcing of clobetasol propionate API?

Clobetasol propionate itself is a well-established molecule, and its primary composition of matter patents have long expired. However, sourcing can still be influenced by:

• Process Patents: Patents covering novel or improved synthesis routes, purification methods, or specific polymorphic forms of clobetasol propionate may exist. Sourcing from a manufacturer that utilizes a non-infringing process is essential. Companies must conduct freedom-to-operate (FTO) analyses to ensure their chosen API source does not infringe on existing process patents.
• Formulation Patents: While not directly related to API sourcing, patents covering specific topical formulations of clobetasol propionate can influence the demand and competition in the finished product market, indirectly affecting API manufacturers.
• Exclusivity Periods: For newer generic versions, data exclusivity or market exclusivity granted to the first generic applicant could influence demand for API from certain manufacturers.

What are the typical impurity profiles to monitor for clobetasol propionate API?

Monitoring impurity profiles is a cornerstone of API quality control. For clobetasol propionate, common impurities to monitor include:

• Starting Materials and Intermediates: Residual amounts of raw materials or intermediate compounds used in the synthesis.
• By-products: Unintended compounds formed during chemical reactions.
• Degradation Products: Compounds formed from the breakdown of clobetasol propionate under specific storage or manufacturing conditions (e.g., hydrolysis, oxidation).
• Isomers: Related structural isomers of clobetasol propionate.
• Stereoisomers: Enantiomers or diastereomers if applicable to the synthesis route.
• Potentially Genotoxic Impurities (PGIs): Specific impurities that may pose a genotoxic risk and require very stringent control limits, often at parts per million (ppm) levels. Examples could include alkylating agents or specific reactive intermediates, depending on the synthesis.

Regulatory guidelines, such as ICH Q3A(R2) for new drug substances and ICH M7 for PGIs, define thresholds for reporting, identification, and qualification of impurities.

What are the supply chain risks associated with clobetasol propionate API?

Potential supply chain risks include:

• Geopolitical Instability: Disruptions in major manufacturing regions (e.g., India, China) due to political unrest, trade wars, or natural disasters can impact supply.
• Regulatory Changes: Evolving regulatory requirements or crackdowns on environmental non-compliance in manufacturing countries can lead to supply interruptions or increased costs.
• Quality Failures: Batch failures or recalls due to GMP non-compliance or quality deviations at the API manufacturing site.
• Consolidation of Manufacturers: A limited number of key suppliers can create dependency and vulnerability if one supplier faces issues.
• Raw Material Shortages: Dependence on specific raw materials for synthesis can lead to shortages if upstream suppliers face production problems.
• Logistical Challenges: Transportation delays, customs issues, or increased freight costs can affect timely delivery.

How do analytical methods ensure API quality?

A suite of validated analytical methods is essential for characterizing and controlling clobetasol propionate API quality. Key methods include:

• High-Performance Liquid Chromatography (HPLC): The primary method for assay determination and related substances analysis, providing separation and quantification of clobetasol propionate and its impurities.
• Gas Chromatography (GC): Used for the analysis of residual solvents.
• Karl Fischer Titration: For precise determination of water content.
• Spectroscopy (UV-Vis, IR, NMR, Mass Spectrometry): Used for identification, structural elucidation of impurities, and confirmation of API identity.
• X-ray Powder Diffraction (XRPD): To confirm the crystalline form (polymorph) of the API.
• Particle Size Analysis (e.g., laser diffraction): To characterize particle size distribution.
• Thermal Analysis (DSC, TGA): To study thermal properties and polymorphic transitions.

These methods must be validated according to ICH Q2(R1) guidelines to ensure accuracy, precision, specificity, linearity, and robustness.

Key Takeaways

Clobetasol propionate API sourcing relies on a global network of specialized manufacturers, with India, China, and Europe as primary production centers. Stringent quality control, adherence to pharmacopoeial standards (USP, EP), and robust regulatory compliance (FDA, EMA) are paramount. Key considerations for supplier selection include GMP certification, DMF availability, supply chain reliability, and technical capabilities. While composition of matter patents have expired, process patents and freedom-to-operate analyses remain relevant. Continuous monitoring of impurity profiles, especially for PGIs, and proactive management of supply chain risks such as geopolitical instability and quality failures are critical for ensuring a secure and compliant supply of clobetasol propionate API.

---

Frequently Asked Questions

1. Can I source clobetasol propionate API from a manufacturer without FDA or EMA GMP certification?

No. For commercialization in the U.S. and EU markets, API manufacturers must demonstrate compliance with Current Good Manufacturing Practices (cGMP) as assessed by the FDA and/or EMA. An FDA inspection or a valid CEP from the EDQM are typically required for regulatory filings.

2. What is the significance of a Drug Master File (DMF) for clobetasol propionate API?

A DMF is a submission to a regulatory agency (like the FDA) that provides confidential, detailed information about the manufacturing process, facilities, quality control, and specifications of an API. It allows the API manufacturer to protect proprietary information while enabling regulatory agencies to review the API's suitability for use in a finished drug product.

3. How is polymorphism controlled for clobetasol propionate API?

Polymorphism is controlled through specific crystallization conditions (e.g., solvent systems, temperature, cooling rates) and is confirmed using techniques like XRPD and DSC. API manufacturers will specify and consistently produce the desired polymorphic form to ensure predictable dissolution and stability characteristics in the final formulation.

4. What is the typical shelf life of clobetasol propionate API?

The shelf life of clobetasol propionate API is determined by stability studies conducted under ICH guidelines. Typically, it can range from 2 to 5 years when stored under specified conditions (e.g., protected from light and moisture, at controlled room temperature), but this must be confirmed by the specific manufacturer's Certificate of Analysis and stability data.

5. How often are API manufacturers audited by regulatory bodies?

The frequency of regulatory inspections varies. The FDA may inspect facilities on a risk-based schedule, which could be every 2-5 years or more frequently if compliance issues are identified. EMA inspections are often conducted by national competent authorities within EU member states, with similar risk-based scheduling. Manufacturers also undergo regular audits by their pharmaceutical clients.

---

Citations

[1] U.S. Food and Drug Administration. (n.d.). Guidance for Industry Drug Master Files. Retrieved from [FDA Website] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM Website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Tripartite Guideline Impurities: Guidelines for New Drug Substances Q3A(R2). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2017). ICH Harmonised Guideline on Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R2). [5] United States Pharmacopeial Convention. (2023). United States Pharmacopeia. [6] European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia.